Piper Sandler Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $232

Piper Sandler analyst David Amsellem has maintained an Overweight rating on Jazz Pharmaceuticals (NASDAQ: JAZZ) and increased the price target from $219 to $232.